Arsanis, Inc. releases salary data. CEO sees compensation rise 21%

Arsanis, Inc. just filed its annual proxy statement, which details the salary information of its key executives. In 2018, the company's CEO made 921,027.

The table is included below:

Name and Principal Position (1)

Year Salary
($)
Bonus
($) (2)
Stock
Awards
($) (3)
Option
Awards
($) (3)
Non-equity
Incentive Plan
Compensation
($) (4)
All Other
Compensation
($) (5)
Total ($)

Paula Ragan, Ph.D.

2018 380,000 — — 407,577 133,000 450 921,027

President, Chief Executive

Officer and Secretary

2017 364,000 — — 303,422 89,180 576 757,178

Adam S. Mostafa (6)

2018 109,285 — — 480,789 38,250 90 628,414

Chief Financial Officer and

Treasurer

Michael Gray, M.B.A., C.P.A.

2018 405,193 181,136 1,030,000 1,310,947 — — 2,927,276

Former President, Chief

Executive Officer and Chief

Financial Officer

2017 363,077 231,525 — 262,090 — — 856,692

David Mantus, Ph.D.

2018 358,750 — — 595,885 — 120,250 1,074,885

Former Chief Development

Officer

2017 313,750 — — 117,926 — — 431,676

René Russo, Pharm.D., BCPS

2018 405,866 — — 1,906,833 — 1,046,250 3,358,949

Former President and Chief

Executive Officer

2017 388,750 254,100 — 524,182 — — 1,167,032

Christopher Stevens, M.D.

2018 380,000 — — 595,885 — 329,333 1,305,218

Former Chief Medical Officer

2017 380,000 159,600 — 117,937 — — 657,537

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Arsanis, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

Departure of Directors or Certain - March 20, 2020
Entry into a Material Definitive - March 17, 2020
Securities to be offered to employees in employee benefit plans - March 13, 2020
Arsanis, Inc. Just Filed Its Annual Report: Net Loss per Share— ... - March 12, 2020
Arsanis: X4 Pharmaceuticals Provides Corporate Update And Reports Fourth Quarter And Full Year 2019 Financial Results - March 12, 2020

Auto Refresh

Feedback